INTRODUCTION
============

The core symptoms of schizophrenia include the presence of delusions and hallucinations (positive symptoms), apathy, and social withdrawal (negative symptoms), as well as, stable impairments in specific domains of cognitive function. Despite our best effort, we still lack a basic understanding of the etiopathogenesis of schizophrenia and therefore tools for curative treatment or prevention do not exist ([@B26]). Given the high prevalence of schizophrenia (1% or more) the need for greater understanding is urgent.

Most efforts in understanding the cellular basis of schizophrenia have followed a "neuron-centric" approach, focusing exclusively on the role(s) of neurons. This has led to findings of alterations in neuronal function, such as neurotransmission and synapse cytoarchitecture, often overlooking the fact that neuronal function and neurotransmission is inextricably dependent on interactions between neurons and glia. Increasing recognition of the importance of neuro-glial elements as basic functional units ([@B4]) that participate in CNS function and dysfunction combined with multiple lines of evidence showing abnormalities in oligodendrocytes and myelination have implicated oligodendrocytes as highly relevant to schizophrenia. While the approach of grouping neurons and glia into neuro-glial functional units introduces significant complexity into the analysis of the neurobiology of schizophrenia, it encourages an integrative approach that favors the examination of the interplay between neurons and the more abundant glial cell types of the CNS.

Here, we first outline genetic evidence derived from candidate gene association studies or genome-wide approaches that support oligodendroglial and myelin related (OMR) abnormalities in schizophrenia as a primary contributor. In an attempt to provide a mechanistic and integrative interpretation of the neuronal and OMR changes in schizophrenia, we introduce a neuro-oligodendroglial model that involves abnormalities at the nodes of Ranvier (NOR) as a functional unit implicated in the etiopathogenesis of the disease.

MYELIN ASSOCIATED ABNORMALITIES IN SCHIZOPHRENIA
================================================

Myelination can increase action potential transmission speed and decrease refractory time, which increases the number of action potentials that can be transmitted per unit time. There is accumulating evidence supporting the notion of schizophrenia as a disorder of disconnectivity ([@B32]). While disconnectivity can be caused by different mechanisms, such as synaptic malfunction, at its core, it implicates inadequate or failed information transfer among neurons. OMR abnormalities in schizophrenia impair the saltatory conduction and information conduction from one neuron to others.

Growing evidence, accumulated over the last 15 years, provide strong support for OMR abnormalities in schizophrenia. The majority of those data is derived from neuroimaging and human postmortem studies (for review, see [@B63]; [@B18]). Irrespective of the level of care and control, different confounding factors, such as antipsychotic medication, could contribute to the detected OMR neuroimaging, gene expression, and proteome abnormalities in schizophrenia. Therefore, incorporating genetic data, as discussed below, can help distinguish whether OMR changes are a primary contributor to disease pathophysiology vs. secondary changes associated with other primary lesions existing in schizophrenia or mere epiphenomena.

GENETIC ASSOCIATION OF OMR CANDIDATE GENES IN SCHIZOPHRENIA
-----------------------------------------------------------

Multiple candidate studies have provided evidence that OMR genes are genetically associated with schizophrenia (**Table [1](#T1){ref-type="table"}**). It is interesting to note, that the products of these same genes have been implicated in numerous direct studies of OMR gene and protein expression in the brains of persons with schizophrenia, as well as, neuroimaging studies, providing a stronger support for causality with the disease ([@B8]; [@B70]). The OMR genes with the strongest support for genetic association with schizophrenia are described below:

###### 

OMR genes implicated in schizophrenia.

  Gene        Genetic evidence                                PGC-SWE P   Rank   Altered gene expression                         Altered proteome
  ----------- ----------------------------------------------- ----------- ------ ----------------------------------------------- ------------------
  *ANK3*      [@B5], [@B60], [@B79]                           1.31E-05    2      [@B60]                                          [@B14], [@B60]
  *CLDN11*                                                    9.04E-05    5      [@B72], [@B28], [@B16], [@B60],[@B1])           
  *CNP*       [@B48], [@B73]                                  3.94E-03    19     [@B22], [@B28], [@B16], [@B41], [@B7], [@B61]   [@B50], [@B16]
  *CNTNAP2*   [@B19], [@B75], [@B27]                          3.95E-04    10     [@B60]                                          
  *DISC1*     [@B43], [@B62], [@B66], [@B53], [@B6], [@B15]   1.04E-03    13     [@B44]                                          [@B54]
  *ERBB3*     [@B35]                                          9.70E-05    6      [@B72], [@B28], [@B61]                          
  *ERBB4*     [@B46], [@B64], [@B3]                           2.80E-06    1      [@B64], [@B33]                                  [@B12]
  *MAG*       [@B74], [@B77]                                  1.96E-03    16     [@B72], [@B28], [@B16], [@B41], [@B7], [@B61]   
  *MAL*                                                       8.23E-03    21     [@B22], [@B28]                                  
  *MBP*       [@B6]                                           4.23E-04    11     [@B72], [@B40]                                  [@B8],[@B9])
  *MOBP*      [@B6]                                           6.65E-03    20     [@B72]                                          
  *MOG*       [@B36]                                          1.00E-02    23     [@B72], [@B28], [@B7], [@B61]                   [@B38]
  *NFASC*                                                     2.57E-04    8      [@B60]                                          
  *NRCAM*     [@B6]                                           1.14E-03    14     [@B60]                                          
  *NRG1*      [@B69], [@B6], [@B76], [@B3]                    3.24E-05    3      [@B25], [@B34], [@B71]                          [@B12]
  *OLIG2*     [@B20]                                          2.13E-03    17     [@B72], [@B28]                                  
  *PLP1*      [@B51]                                          NA          NA     [@B72]                                          
  *PMP22*     [@B30]                                          1.38E-03    15     [@B28], [@B16]                                  
  *PTPRZ1*    [@B10]                                          6.21E-05    4                                                      
  *QKI*       [@B2], [@B6]                                    1.08E-04    7      [@B28], [@B1], [@B41]                           
  *RTN4R*     [@B9]                                           6.75E-04    12                                                     
  *SOX10*     [@B37], [@B78]                                  8.24E-03    22     [@B72], [@B28], [@B16]                          
  *CNTN2*                                                     2.57E-04    8      [@B60],[@B1]                                    
  *TF*        [@B52]                                          2.25E-03    18     [@B22], [@B28], [@B41], [@B61]                  [@B50]

The largest PGC-SWE (
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) in the form of summary statistic

p

-values was obtained from public access website (
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). For each gene (±100 kb from 5′ and 3′ ends of gene), the strongest

P

value association is provided in the "PGC-SWE

P

" column. The "Rank" column indicates the ranking of the illustrated genes based on the strength of association with the schizophrenia GWAS data set.

### Neuregulin 1 (NRG1) -- ERBB4 signaling

*NRG1* risk genotypes or haplotypes have been associated with schizophrenia ([@B69]). Genetic evidence also supports *ERBB4* -- the *NRG1* receptor -- as a candidate susceptibility gene and suggests positive epistatic interactions between *NRG1* and *ERBB4* in schizophrenia ([@B46]). The potential pathophysiologic role of *NRG1* is further supported by its diverse neurobiological functions, including neuro-glial trophic effects and myelination ([@B24]). Nevertheless, given the fact that the *NRG1* -- *ERBB4* signaling has multiple effects in nervous system development (including neuronal migration and modulation of neurotransmission), this pathway may play a role in schizophrenia pathogenesis through other mechanisms aside from OMR effects. A direct way to assess the pathophysiologic effects of genetic variants would be to examine human subjects with risk variants for symptoms of schizophrenia. Along these lines, many groups have reported association of the *NRG1* -- *ERBB4* risk variants with neurocognitive ([@B68]), electrophysiological ([@B59]) and neuroimaging schizophrenia-related outcome variables, including altered fronto-temporal brain function ([@B23]) and white matter density and integrity ([@B42]; [@B31]). Finally, several groups have assessed gene expression and proteins of *NRG1* and *ERBB4* in postmortem brains and have reported differences between schizophrenia and healthy control groups ([@B25]; [@B34]).

### Disrupted-in-schizophrenia 1

*Disrupted-in-schizophrenia 1 (DISC1)* is a strong candidate gene for schizophrenia and was initially identified in a large Scottish pedigree ([@B43]) followed by additional genetic evidence for association with sporadic cases of schizophrenia ([@B13]). Recent studies in zebrafish ([@B17]) and transgenic mice ([@B29]) with forebrain restricted expression of mutant human *DISC1* have suggested a critical role for *DISC1* in oligodendroglial differentiation during neurodevelopment. In human postmortem analyses, *DISC1* transcripts that are more abundant during fetal development are upregulated in the hippocampus of patients with schizophrenia and their expression levels are associated with schizophrenia risk *DISC1* polymorphisms ([@B44]). One of those risk *DISC1* SNPs is also associated with white matter integrity as measured by DTI ([@B67]).

### Reticulon 4 receptor

*Reticulon 4 receptor (RTN4R)* is a myelin-associated protein that inhibits the outgrowth of neurites and nerve terminals ([@B11]). *RTN4R* is upregulated in the brains of patients with schizophrenia ([@B47]). Genetic evidence supports a role of *RTN4R* in the etiopathogenesis of schizophrenia ([@B47]; [@B9]). Interestingly, *in vitro* experiments demonstrated that cultured neurons expressing the schizophrenia-associated *RTN4R* variants failed to respond to the growth inhibiting activity of myelin, and functioned as a dominant negative to disrupt endogenous *RTN4R*([@B9]).

### Other genes

Oligodendrocyte lineage transcription factor 2 (*OLIG2*) encodes a transcription factor central to oligodendrocyte development ([@B57]). Genetic association analysis showed that *OLIG2* is associated with schizophrenia and demonstrated an epistatic effect with 2′,3′-cyclic nucleotide 3′-phosphodiesterase (*CNP*) and *ERBB4*([@B20]). Furthermore, *OLIG2* expression significantly correlated in cerebral cortex with *CNP* and *ERBB4*, suggesting that variation in *OLIG2* confers susceptibility to schizophrenia as part of a network of genes implicated in oligodendrocyte function. Similarly, a genetic association of the CNP gene was found for schizophrenia ([@B48]). The CNP risk polymorphism was associated with lower gene expression which is consistent with CNP gene expression downregulation in schizophrenia.

GENETIC ASSOCIATION OF OMR GENES IN SCHIZOPHRENIA DERIVED FROM GENOME-WIDE APPROACHES
-------------------------------------------------------------------------------------

Significant progress has been made over the last decade through large genome-wide association studies (GWAS). The GWAS design has provided evidence in an agnostic manner that specific common DNA genetic variants among people influence their genetic susceptibility to multiple different complex disorders, including schizophrenia ([@B56]). Furthermore, we have learned that the genetic risk for schizophrenia is highly polygenic ([@B56]), where the phenotype is influenced by multiple genetic variants, each one with small effect sizes. Here, we present results for association of each OMR gene with schizophrenia according to the largest published schizophrenia GWAS data set (PGC-SWE;<https://pgc.unc.edu/>; [@B56]). No OMR genetic association reached genome-wide significance (**Table [1](#T1){ref-type="table"}**); however, a handful of OMR genes (*ANK3, ERBB4,*and*NRG1*) show suggestive association (*P* \< 5 × 10^-5^). Future GWAS with increased sample sizes will determine whether OMR genetic variants are true associations at reduced thresholds, but without the needed power to reach genome-wide significance.

Systems biology approaches allow the integration of multi-scale datasets gained from genetic imaging and gene and protein expression studies. The risk SNPs are unlikely to be randomly distributed, but cluster in molecular subnetworks affecting specific cellular populations and molecular processes ([@B58]; **Figure [1A](#F1){ref-type="fig"}**). Recent findings support the notion that polygenic risk for schizophrenia affects OMR gene networks and molecular pathways ([@B61]; [@B21]). Perturbations in specific subnetworks related to neuronal function, myelination, immune response, and energy production were identified in a multi-regional system-level analysis of the schizophrenia brain transcriptome ([@B61]). The subnetworks related to neuronal function and myelination were enriched for genetically associated variants in schizophrenia, providing independent support for the neuro-oligodendroglial interactions as a potential causal functional unit in schizophrenia. No enrichment for genetic variants and immune response and energy production related subnetworks was found, suggesting that these changes may represent secondary or bystander phenomena or be attributable to environmental influences. Similar results were reported in an independent study, in which the genetic evidence for primary roles of specific glial cell type functions and pathways was examined based on gene set analysis ([@B21]). In conclusion, recent systems biology approaches support the notion that schizophrenia involves hundreds of genetic loci that in combination with environmental factors converge to perturb a more selective/restrictive set of molecular/cellular networks and integrative functions.

![**Neuro-glial functional unit and the disconnectivity syndrome in schizophrenia.** **(A)** Constellations of multiple genetic and environmental perturbations affect molecular states of gene coexpression and protein--protein interaction networks in the neuro-glial functional unit that in turn increase the risk for schizophrenia. **(B)** The NOR is the site of intimate neuroglial cell--cell interactions in the nervous system. Abnormalities in the expression of NOR genes and proteins in schizophrenia hamper saltatory conduction by affecting NOR formation, maintenance and integrity and lead to the disconnectivity syndrome.](fncel-08-00005-g001){#F1}

FUNCTIONAL NEURO-GLIAL UNITS AND THE NODES OF RANVIER
=====================================================

The above observations suggest that genetic alterations underlying OMR cell type functions increase susceptibility to schizophrenia and provide evidence that the "neuron-centric" hypothesis of schizophrenia should be extended to include a role for glia in the etiopathogenesis of the disease. The NOR is one of the best example of the neuroglial cell--cell interactions in the central nervous system. The NORs are myelin-sheath-free segments along myelinated axons, where sodium ion exchange takes place propagating action potentials from the axon initial segment to the axon terminal. NOR and OMR gene and protein expression abnormalities can hamper saltatory conduction by affecting NOR formation, maintenance, and integrity, which in turn leads to failures of saltatory conduction and disconnection of higher-order association areas ([@B45]).

Different and specific neuronal and oligodendroglial reciprocal interactions (for review, see [@B49]) ensure the high concentration and anchoring of voltage gated Na^+^ channels (Na~V~; Na~V~1.6 in adults -- *SCN8A*) to the NOR and the maintenance of adherens junctions between the axolemma and paranodal myelin loops (**Figure [1B](#F1){ref-type="fig"}**). The voltage gated Na^+^ channel cytoplasmic loops are linked to the underlying spectrin-actin cytoskeleton through the anchoring protein Ankyrin G (*ANK3*). *ANK3* plays an important role in the NOR complex by anchoring not only the Na~V~ to the node but also because several *cis*acting nodal and paranodal adherens junction proteins, such as neurofacin (*NFASC*), neuronal cell adhesion molecule (*NRCAM)*, contactin 1 and caspr, are also associated with it. Finally, contactin 2 (*CNTN2*), along with Caspr interact *in trans* with cell adhesion molecules of oligodendroglial paranodal loops that include an isoform of *NFASC* (Nf155), and *CNTN2* to ensure the integrity of the myelin-axolemma tight junctions, which form a barrier that prevents the diffusion of Nav from the nodal region.

A recently study demonstrated that several NOR genes and proteins, including *ANK3*, *NFASC, NRCAM, CNTN2*, and *SCN8A* are affected in schizophrenia ([@B60]). The importance of *ANK3* to serious mental illness is further supported by recent GWAS implicating *ANK3* in schizophrenia ([@B5]) and bipolar disorder ([@B65]). Furthermore, an *ANK3* risk polymorphism is associated with decreased *ANK3* gene expression, which is consistent with *ANK3* gene expression downregulation in schizophrenia and neurocognitive and neuroimaging abnormalities ([@B60]). Overall, these data highlight that in addition to OMR changes in schizophrenia, abnormalities in how myelin sheaths interact with the axon to form the NOR are also present and identify the NOR as a functional neuro-glial unit where neuronal and OMR genetic perturbations could potentially converge.

Conclusion
==========

There are multiple lines of evidence derived from neuroimaging, molecular and genetic data that support a role of OMR genes and molecular pathways in schizophrenia. Recent systems biology and pathway analyses that integrate gene expression and genetic data support the notion that oligodendroglial abnormalities are among the primary deficits in the disorder. Future studies need to integrate the larger GWAS and determine the polygenic effect of OMR genes in schizophrenia. While most efforts in understanding the cellular basis of schizophrenia have followed a "neuron-centric" approach, there is an emerging need to conduct more complex neurobiological studies and examine the neuro-glial unit as a whole. The data to date provide evidence for abnormalities in the NOR as a plausible biological substrate for the disconnectivity syndrome in schizophrenia. Recent evidence suggesting that antipsychotics may influence OMR function beneficially provides clues for improved treatment strategies ([@B55]). Therefore, a more thorough understanding of the role of OMR and NOR pathophysiology is necessary since it holds the potential for providing new insights into the treatment of this disease.
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